Name
Capella University
NURS-FPX4015 Pathophysiology, Pharmacology, and Physical Assessment: A Holistic Approach to Patient-Centered Care
Prof. Name
Date
Greetings! My name is _____. Today, I will perform a complete head-to-toe assessment of my Sentinel U case study patient, Aiyana Tehanata. She reports two months of persistent tingling in her feet, along with pain. She describes it as burning, sharp, or stinging, rated 5 out of 10. Her past medical history includes hypertension and hyperlipidemia, and she currently presents with elevated blood glucose and evidence of Coronary Heart Disease (CHD). This assessment will cover her cardiovascular condition, respiratory function, and overall systemic health.
I would like to explain the steps of the evaluation so that you feel at ease and fully aware of what to expect. This will be a thorough physical evaluation, covering all body systems, with attention to your reported concerns. It includes foot tingling, moderate discomfort rated 5 out of 10, and elevated blood sugar levels. The general examination will start with an overall review of your health status, emphasizing vital functions. During the skin assessment, I will examine the surface for texture, temperature, color, and nail integrity. Irregular patterns in these observations suggest reduced blood flow, a typical outcome of raised glucose levels. On inspection, your feet appear dry and red, though no open lesions are present.
The dryness and peeling skin may be consistent with autonomic neuropathy, a complication linked to uncontrolled diabetes. Additionally, evaluating the temperature of the lower extremities helps to detect circulatory disturbances, as temperature variations reflect problems in vascular flow. Research shows that patients with diabetes and vascular disease have cooler foot temperatures than those without such conditions (Balasubramanian et al., 2021). Following this, I conduct a vascular assessment by palpating the dorsalis pedis and posterior tibial pulses. The diminished quality of these pulses suggests compromised peripheral circulation. It is a recognized complication of diabetes-related vascular disease.
As part of the assessment, I examine your eyes to check for any early signs of diabetes-related complications. Your pupils react normally to light. However, I advise scheduling an appointment with an ophthalmologist for a complete evaluation to exclude diabetic retinopathy. As time progresses, diabetes can adversely impact vision, causing visual impairment, retinopathy, or even blindness (Upadhyay et al., 2024). Moving to the neurological portion of the exam, I emphasize your feet since you have reported tingling and burning discomfort. I begin by assessing the pulse quality, then proceed with monofilament testing to evaluate pressure sensation across different areas of the feet.
In some regions, you demonstrate only partial awareness of the stimulus. This suggests the probability of peripheral neuropathy, a condition linked to diabetes. This information helps determine the degree of nerve impairment caused by elevated glucose levels. I encourage you to communicate any changes in sensation and worsening pain during the procedure. These findings support neuropathic involvement related to diabetes. You reported tingling and burning primarily in the toes. Peripheral neuropathy in diabetic patients is characterized by numbness, burning, or tingling that intensifies during the night (Chang & Yang, 2023).
Next, we will focus on the cardiovascular evaluation to assess your blood pressure and cardiac function, given your history of hypertension. This step is essential, as elevated blood sugar and high blood pressure increase the risk of cardiovascular disease. I begin by placing a blood pressure cuff on your arm to obtain an accurate reading and use a stethoscope to listen to your heart sounds. During auscultation, I detect turbulent flow at the 4th Intercostal space (ICs). This indicates disrupted blood flow due to narrowed or stiffened heart valves or blood vessels, commonly associated with CHD.
Lastly, I evaluate your musculoskeletal function. Your hand grip strength is reduced, possibly reflecting fatigue. You have also reported dizziness. Assessment of lower extremity mobility reveals mild stiffness, related to reduced oxygen delivery to tissues. Persistently elevated glucose levels can cause inflammation and nerve damage, leading to numbness, tingling, and discomfort (Chang & Yang, 2023). This concludes your complete assessment, providing valuable information to guide a personalized care plan. Thank you for your cooperation during the examination.
After completing a full head-to-toe assessment, I have observed several important findings that have emerged, clarifying Aiyana’s health status and guiding an accurate diagnosis. Her primary concerns included tingling in the feet, elevated blood glucose, and hyperlipidemia. Examination of the skin revealed dryness and redness without any open lesions or wounds. These dermatologic changes suggest impaired peripheral circulation, a common complication of diabetes. This can contribute to pain and tingling in the toes (Chang & Yang, 2023). Vascular assessment showed weakened pedal pulses in both the posterior tibial and dorsalis pedis arteries. Neurological evaluation using a monofilament demonstrated reduced sensation in multiple areas of the feet.
You reported increased tingling in specific areas. This is an indication of diabetic peripheral neuropathy. This condition occurs when persistent high blood sugar damages small peripheral nerves in the extremities. This results in burning, numbness, or sharp, stinging pain. Cardiovascular examination revealed elevated blood pressure, and I noticed turbulent flow at the ICs on auscultation. This suggests compromised ventricular function associated with hypertension. The patient’s medical history and these findings support a primary diagnosis of CHD. Symptoms such as dizziness, lightheadedness, and foot numbness reflect circulatory insufficiency. This is commonly seen in individuals with CHD.
High blood pressure and irregular cardiac rhythms suggest that the heart is under strain, while constricted blood vessels reduce the efficiency of blood flow throughout the body. Chronic high blood sugar contributes to inflammation and oxidative damage. This affects both cardiac tissue and arterial walls (Geest & Mishra, 2022). During the musculoskeletal evaluation, I observed slight weakness in your lower extremities and diminished hand grip strength. This results from fatigue caused by impaired circulation and reduced oxygen delivery to muscles.
You have combination hyperglycemia, elevated blood pressure, abnormal lipid levels, and decreased foot sensation point to multiple complications. These findings support a primary diagnosis of CHD and a secondary diagnosis of Diabetes Peripheral Neuropathy (DPN). Early recognition and management are essential to prevent complications and improve health outcomes. You can reduce symptoms through consistent adherence to prescribed medications, regular blood glucose monitoring, and the adoption of a heart-healthy lifestyle.
Your current clinical presentation and diagnoses indicate that the treatment plan should target CHD and DNP. Management of CHD aims to reduce the heart’s workload, enhance oxygen delivery, and prevent disease progression. Common medications for controlling high blood pressure and CHD include beta-blockers, such as metoprolol, and lipid-lowering agents like atorvastatin. You are currently taking metoprolol 50 mg. This decreases heart rate, blood pressure, and cardiac strain. Atorvastatin helps lower cholesterol and limit plaque formation in the arteries. These medications require careful monitoring.
Statin therapy can cause liver toxicity, muscle disorders, kidney impairment, cataracts, and increased risk of hyperglycemia (Ruscica et al., 2022). Because of your history of elevated blood glucose, close observation is essential when using beta-blockers to avoid complications. An overdose of metoprolol results in serious effects on the heart, blood pressure, respiratory system, and nervous system. Other side effects include fatigue, dizziness, and difficulty breathing (Mood et al., 2023).
Gabapentin is frequently prescribed to manage nerve pain and tingling associated with DPN. It works by modulating calcium channels in the central nervous system. This decreases nerve hyperexcitability and helps relieve the discomfort and burning sensations you have been experiencing. Potential side effects of gabapentin include dizziness, fatigue, mood changes, risk of self-harm, withdrawal-related seizures, multi-organ irritation, and generalized systemic symptoms (Russo et al., 2022). Your healthcare provider recommends a biguanide, such as metformin, to help regulate blood glucose levels. This medication aids in maintaining glycemic control, reducing the risk of nerve damage, and preventing the progression of diabetes-related complications. Your current hyperglycemia makes strict blood sugar management essential to safeguard your nerves and health.
You reported that you are using Tung seed, which you have been using for hair growth. This requires caution because herbal supplements can interact unpredictably with prescription medications. It is advisable to discontinue its use for now and discuss all herbal products with your healthcare provider. Certain herbs can affect the absorption, metabolism, and efficiency of medications, reducing their benefits and causing adverse effects (Auxtero et al., 2021). Your pharmacologic plan should be carefully planned to minimize harmful interactions and overlapping side effects. For example, gabapentin requires precise dosing and regular monitoring of kidney function. Abrupt discontinuation of medications, such as gabapentin and beta-blockers, can lead to withdrawal symptoms and worsen cardiac conditions. Proper management of DPN and CHD depends on selecting appropriate therapies and monitoring your health status.
A clear understanding of pathophysiology will help you understand how diabetes contributes to DPN and CHD. CHD arises when atherosclerotic plaque builds up in the arteries, restricting blood stream and lowering oxygen supply to the cardiac system. This condition affects the myocardium and the blood vessels that supply it. Insufficient oxygen to the cardiac tissue can trigger signs like pain in chest and difficulty in breathing. This impairs heart function. Diabetic patients exhibit lipid imbalances, including elevated triglycerides, low levels of high-density lipoprotein cholesterol, and an excess of small, dense low-density lipoprotein. This accelerates atherosclerosis and exacerbates cardiac complications (Pan et al., 2024). Common signs include dizziness and fatigue. You may observe palpitations, chest tightness, and difficulty breathing. If the disease progresses, it can lead to tachycardia or cardiac arrest.
The secondary diagnosis, DPN, disrupts the capacity to manage blood sugar levels. Chronic hyperglycemia promotes insulin resistance, triggering oxidative stress, inflammation, and cellular injury. Firstly, injury happens in distal sensory and autonomic nerve fibers. This extends proximally, resulting to a persistent damage of defensive feeling in the skin and joints of the feet (Geest & Mishra, 2022). Elevated blood sugar contributes to fat accumulation within the arteries. This narrows blood vessels and reduces circulation to the lower extremities, which manifests as foot pain, tingling, and other common symptoms of DPN.
Microvascular alterations impair nerve blood supply, worsening neuropathic damage. Patients with DPN report sensations such as burning, numbness, tingling, limb weakness, heightened pain sensitivity (allodynia), and episodic discomfort. This intensifies at night (Chang & Yang, 2023). Uncontrolled hyperglycemia can lead to severe consequences. This includes poor circulation and progressive nerve injury. Cardiovascular strain promotes inflammation in the lower limbs, while persistent hyperglycemia continues to damage cells and tissues, including the heart and arteries (Geest & Mishra, 2022).
These conditions are interconnected. CHD reduces systemic circulation, including to the extremities, while diabetes amplifies vascular and nerve damage. You are currently experiencing pain, numbness, fatigue, and weakness, which can worsen. This affects daily functioning. Consistent medication adherence, blood sugar monitoring, and a healthy lifestyle are vital to controlling DPN and CHD, minimizing complications.
A comprehensive assessment of Aiyana highlights her needs regarding medications, disease management, and clinical symptoms. This serves as the foundation for establishing her primary care priorities. These priorities align with current evidence-based clinical recommendations and focus on controlling hyperglycemia to slow neuropathy progression, managing cardiovascular risk factors, addressing pain and other symptoms, and implementing strategies to reduce complications. The foremost care goal is achieving optimal blood glucose control to prevent the development of DPN. The American Diabetes Association (ADA) suggests an HbA1c levels below 7% for most adult patients with diabetes (ADA, 2025).
Management includes pharmacologic interventions such as metformin and, if necessary, insulin therapy, tailored to the severity of her hyperglycemia. Lifestyle modifications are vital. It encompasses implementing balanced food and daily excercise. Emphasis should be placed on portion control, minimizing intake of sugary foods, and limiting alcohol consumption to support glycemic regulation.Another key care focus is reducing the complications associated with CHD. Aiyana’s history of hypertension and hyperlipidemia, along with diminished peripheral pulses and turbulent flow at the 4th ICs, supports the presence of CHD. Healthcare providers prescribe antihypertensive and cholesterol reducing medicines, such as metoprolol and atorvastatin.
Continuous observation of blood pressure and lipid levels is vital to evaluate treatment efficacy and detect potential adverse effects. The American Heart Association (AHA) identifies metoprolol as a first-line beta-blocker for hypertension management. Implementing lifestyle approaches like following the DASH diet (Dietary Approaches to Stop Hypertension) are crucial in reducing cardiovascular risk and supporting long-term heart health (Sangouni et al., 2024).Managing pain and numbness associated with DPN is a key care focus. Pharmacologic therapy, such as gabapentin, helps to reduce discomfort by modulating calcium channels in the central nervous system and decreasing nerve hyperexcitability.
Another important priority is patient education on medication adherence, routine foot care, and lifestyle modifications to support management of CHD and diabetes-related complications. Reducing cardiovascular risk involves guidance on the DASH diet, emphasizing higher intake of fruits and vegetables and limiting sodium consumption. A heart-healthy diet based on DASH principles can improve cardiac function and help maintain optimal blood pressure (Sangouni et al., 2024). Maintaining glycemic control requires minimizing sugary foods and engaging in regular physical activity. For foot care, the American Diabetes Association (ADA) recommends a full foot examination at least annually, with more frequent checks for patients at higher risk (ADA, 2025). Applying these evidence-based strategies allows Aiyana to manage her condition. This reduces complications and improves her quality of life.
The comprehensive head-to-toe assessment of Aiyana highlights the complex interactions among her CHD, diabetic peripheral neuropathy, hypertension, hyperlipidemia, and hyperglycemia. Key findings, including impaired peripheral circulation, reduced nerve sensation, elevated blood pressure, and abnormal lipid profiles, guide the development of an evidence-based, individualized care plan. The integration of pharmacologic therapy, lifestyle modifications, regular monitoring, and patient education is essential to control blood glucose, minimize cardiovascular risk, neuropathic pain, and prevent complications.
American Diabetes Association. (2025). Understanding A1C test. https://diabetes.org/about-diabetes/a1c
Auxtero, M. D., Chalante, S., Abade, M. R., Jorge, R., & Fernandes, A. I. (2021). Potential herb–drug interactions in the management of age-related cognitive dysfunction. Pharmaceutics, 13(1), 124. https://doi.org/10.3390/pharmaceutics13010124
Balasubramanian, G. V., Chockalingam, N., & Naemi, R. (2021). The role of cutaneous microcirculatory responses in tissue injury, inflammation and repair at the foot in diabetes. Frontiers in Bioengineering and Biotechnology, 9. https://doi.org/10.3389/fbioe.2021.732753
Chang, M. C., & Yang, S. (2023). Diabetic peripheral neuropathy essentials: A narrative review. Annals of Palliative Medicine, 12(2), 390–398. https://doi.org/10.21037/apm-22-693
Geest, B. D., & Mishra, M. (2022). Role of oxidative stress in diabetic cardiomyopathy. Antioxidants, 11(4), 784. https://doi.org/10.3390/antiox11040784
Mood, N., Adib, M., Otroshi, A., Dorooshi, G., & Meamar, R. (2023). A clinical-epidemiological study on beta-blocker poisonings based on the type of drug overdose. Journal of Toxicology, 2023, e1064955. https://doi.org/10.1155/2023/1064955
Pan, J., Li, C., Zhang, J., Sun, Z., Yu, X., Wan, Q., Ruan, Z., Wang, W., & Li, Y. (2024). Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: A cross-sectional study. Lipids in Health and Disease, 23(1). https://doi.org/10.1186/s12944-024-02308-5
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022). Side effects of statins—from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 118(17), 3288–3304. https://doi.org/10.1093/cvr/cvac020
Russo, M., Graham, B., & Santarelli, D. M. (2022). Gabapentin. Friend or foe? Pain Practice, 23(1), 63–69. https://doi.org/10.1111/papr.13165
Sangouni, Hosseinzadeh, M., & Parastouei. (2024). The effect of dietary approaches to stop hypertension (DASH) diet on fatty liver and cardiovascular risk factors in subjects with metabolic syndrome: A randomized controlled trial. BioMed Central Endocrine Disorders, 24(1). https://doi.org/10.1186/s12902-024-01661-x
Upadhyay, T., Prasad, R., & Swapneel Mathurkar. (2024). A narrative review of the advances in screening methods for diabetic retinopathy: Enhancing early detection and vision preservation. Cureus, 16(2), e53586. https://doi.org/10.7759/cureus.53586
